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Abstract: The transcriptional gene expression patterns of Chlamydia trachomatis have mainly been 
studied using reference strains propagated in cultured cells. Here, using five low-passage-number 
C. trachomatis clinical isolates that originated from asymptomatic or symptomatic female patients, 
the in vitro expression of the ompA, cpaf, tarp, and tox genes was studied with reverse transcriptase 
real-time PCR during the chlamydial developmental cycle. We observed dissimilarities in the gene 
expression patterns between the low-passage-number clinical isolates and the reference strains. The 
expression of ompA and the peak of the tox expression were observed earlier in the reference strains 
than in most of the clinical isolates. The expression of cpaf was high in the reference strains compared 
with the clinical isolates at the mid-phase (6–24 hours post infection) of the developmental cycle. All 
of the strains had a rather similar tarp expression profile. Four out of five clinical isolates exhibited 
slower growth kinetics compared with the reference strains. The use of low-passage-number C. 
trachomatis clinical isolates instead of reference strains in the studies might better reflect the situation 
in human infection.  
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1. Introduction 
Chlamydia trachomatis urogenital infection is the most common sexually transmitted bacterial 
infection, affecting annually over 100 million individuals worldwide [1]. Most infections remain 
asymptomatic, and untreated or repeated infections can result in pelvic inflammatory disease and 
severe reproductive complications such as infertility and ectopic pregnancy [2]. Based on the ompA 
gene encoding the major outer membrane protein (MOMP), C. trachomatis can be classified in 
genotypes (A-C, D-K, and L1-L3), of which genotypes D-K cause most of the urogenital infections [3]. 
C. trachomatis is an intracellular pathogen with a special two-phase developmental cycle during 
which the bacteria occur either as infectious elementary bodies (EBs) or as metabolically active 
reticulate bodies (RBs) [4]. Temporal expression of C. trachomatis genes corresponds to the phases of 
the chlamydial developmental cycle [5–7]. Early genes are expressed within one to three hours after 
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endocytosis, mid-cycle genes start expressing during RB replication (6–24 hours post infection (hpi)), 
and late genes are transcribed when the RBs convert back to EBs (24–48 hpi). 
During productive infection, C. trachomatis interacts with the host cells through the effector 
proteins that facilitate the bacterial pathogenicity. Among the most extensively studied chlamydial 
effector proteins are translocated actin-recruiting phosphoprotein (Tarp, CT456), Chlamydia protease-
like activity factor (CPAF; CT858) and chlamydial cytotoxin (CT166). Tarp is translocated into the 
host cell by the chlamydial type III secretion system and tyrosine phosphorylated by host kinases [8]. 
Tarp is involved in signaling events, leading to actin recruitment and to the internalization of the EB, 
and promoting the intracellular survival of Chlamydia [9]. CPAF is a potent type II secreted protease 
detected in the host cell cytosol [10,11]. Many of the previously reported effects of CPAF have been 
questioned [12], but CPAF seems to have a role during the exit of EBs [11]. The chlamydial cytotoxin 
inactivates Rho GTPase Rac1 by glycosylation, inducing the actin depolymerization of the host cell 
[13,14]. In addition, cytotoxin is involved in delayed cell cycle progression [15]. 
Most C. trachomatis gene expression studies have been performed using reference strains 
propagated in the laboratory [6,7]. Long-term laboratory propagation of C. trachomatis changes the 
growth properties and gene expression [16–18]. To our knowledge, only the expression of C. 
trachomatis ompA has been analyzed using both clinical and reference strains throughout the 
developmental cycle [19]. The study concluded that the expression levels of clinical type E strains 
and reference strain type E did not correlate. Our aim was to study the expression of C. trachomatis 
ompA, cpaf, tarp, and tox genes during in vitro infection in the cervical epithelial cell line (HeLa229), 
using low-passage-number clinical isolates. In addition, we wanted to evaluate the expression of the 
same genes in the cervical swab specimens collected from the patients with C. trachomatis infection.  
2. Materials and Methods 
2.1. Patients and Samples 
During 2009–2011, 127 female patients attending the outpatient sexually transmitted infection 
(STI) clinic of Helsinki University Hospital, Helsinki, Finland, and gave informed consent and were 
enrolled to this study. The patients visited the clinic because of symptoms, for follow-up, or because 
of notification by an infected partner. A cervical swab was transported in Aptima Swab Transport 
Medium for C. trachomatis and Neisseria gonorrhoeae testing at HUSLAB (Aptima Combo 2 Assay, 
Hologic, Marlborough, MA, USA) Another cervical swab was placed in Universal Transport Medium 
(UTM) (Copan) for the C. trachomatis culture. Of the 127 specimens, 50 were C. trachomatis nucleic 
acid amplification test (NAAT) positive. The study was conducted in accordance with the Declaration 
of Helsinki, and the protocol was approved by the Independent Institutional Review Board of the 
Hospital District of Helsinki and Uusimaa (15.6.2009; HUSLAB §44/2009) and the Ethics Committee 
of the Department of Medicine, Hospital District of Helsinki and Uusimaa (5.6.2999; §241/2009). 
2.2. C. trachomatis Culture 
The anonymized cervical swabs were cultured in McCoy cells (from Pekka Saikku). The cells in 
24-well plates were inoculated with UTM and centrifuged at 3000× g at 30 C for one hour. BHK-21 
medium supplemented with 10% fetal calf serum, 2 mM glutamine, 20 μg/mL gentamicin, 50 U/mL 
nystatin, 100 μg/mL vancomycin, and 0.5 μg/mL cycloheximide was added, and the plates were 
incubated in 5% CO2 at 35 C for 48 hours. The cells were collected in sucrose–phosphate–glutamate, 
pH 7.2 (SPG), and slowly frozen to −70 C. Blind passage was done for C. trachomatis NAAT positive 
specimens—the cells collected previously in SPG were re-inoculated into McCoy cells (wells with 
glass coverslips and wells as such) with the procedure described above. The growth of C. trachomatis 
was detected by direct immunofluorescence staining with a Pathfinder Chlamydia Culture 
Confirmation System (Bio-Rad, Hercules, CA, USA). The C. trachomatis culture positive isolates were 
genotyped using the method described earlier [20], with modifications [21]. 
Five low-passage-number (passage ≤5) clinical isolates representing the most common 
genotypes of E and F (E127, E129, E142, F175, and F213) were included in this analysis [21]. The 
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characteristics of the patients whose isolates were studied are presented in Table 1. These clinical 
isolates as well as reference strains of type E (Bour, VR-348B) and type F (IC-Cal-3, VR-346) (from 
American Type Culture Collection, ATCC, Manassas, VA, USA) were inoculated onto HeLa229 cells 
(ATCC CCL-2.1) in 24-well plates at a multiplicity of infection (MOI) of 1.0. The plates were 
centrifuged at 3000× g at 30 C for one hour and incubated in 5% CO2 at 35 C for one hour. Minimum 
Essential Medium Eagle Alpha Modification (α-MEM; Sigma-Aldrich, Darmstadt, Germany) 
medium supplemented with 10% fetal calf serum, 2 mM glutamine (GlutaMAX, Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA), 0.5% glucose, 20 μg/mL gentamicin, 50 U/mL nystatin, and 0.5 
μg/mL cycloheximide was added, and the plates were incubated in 5% CO2 at 35 C. After incubation 
for 2, 6, 12, 24, 36, and 48 hours, the cells were collected in ice-cold phosphate-buffered saline. The 
experiment included two technical replicates of the infected cells, and it was repeated once. 
Table 1. Characteristics of the five patients whose C. trachomatis isolates were included in the in vitro 
gene expression assays. 
Isolate Age Sex 
Specimen 
Type 
ompA 
Genotype 
Ctr Serology 
IgG/IgM/IgA 1 
Clinical Features 
Other STIs 
(Gonorrhea, HIV, 
or Syphilis) 
E127 27 F 
Cervical 
swab 
E <32/<20/<20 
Asymptomatic, partner 
infected, probable first Ctr 
infection 2 
none 
E129 20 F 
Cervical 
swab 
E 128/<20/<20 
Asymptomatic, partner 
infected, probable repeated 
Ctr infection 3 
none 
E142 20 F 
Cervical 
swab 
E 32/<20/<20 
Pain in the lower abdomen, 
vaginal discharge, BV, 
repeated Ctr infection 4 
none 
F175 24 F 
Cervical 
swab 
F 32/<20/<20 
Asymptomatic, BV, partner 
infected, repeated Ctr 
infection 4 
none 
F213 21 F 
Cervical 
swab 
F 128/<20/<20 
Asymptomatic, probable 
repeated Ctr infection 3 
none 
BV—bacterial vaginosis; Ctr—C. trachomatis; STI—sexually transmitted infection; HIV—human 
immunodeficiency virus; Sex F—female; 1 MIF (micro-immunofluorescence) serology; 2 Negative C. 
trachomatis NAATs in history, and immunoglobulin G (IgG) antibody negative; 3 Negative C. 
trachomatis nucleic acid amplification tests (NAATs) in history, but IgG antibody positive; 4 Positive 
C. trachomatis NAATs in history. 
2.3. Nucleic Acid Extraction and cDNA Synthesis 
The DNA was extracted from C. trachomatis infected McCoy cells (passage 3 to ≤5) with a DNeasy 
blood and tissue kit (Qiagen, Hilden, Germany) for C. trachomatis genotyping. The DNA was 
extracted from infected HeLa229 cells with a PureLink Genomic DNA Kit (Thermo Fisher Scientific) 
for quantitating C. trachomatis genome equivalents (GEs). The RNA was extracted from an aliquot of 
infected HeLa229 cells stored in a RNAlater Solution (Thermo Fisher Scientific) with RNAqueous-
4PCR Kit (Thermo Fisher Scientific) and treated with two units of DNase using the TURBO-DNA-
free Kit (Thermo Fisher Scientific) to remove trace DNA contamination. In addition, RNA was 
extracted from 44 C. trachomatis NAAT positive and 8 NAAT negative cervical swabs in the Aptima 
Swab Transport Medium (Hologic) with a RNAqueous-4PCR Kit (Thermo Fisher Scientific). 
cDNA was synthesized with a Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo 
Fisher Scientific) using the RNA extracted from HeLa229 cells and cervical samples. A reverse 
transcriptase negative (RT-) control was included for every sample. No-template control was used to 
assess for reagent contamination.  
2.4. Real-Time PCR 
C. trachomatis ompA PCR was performed with a method designed previously [22]. The primers 
and probes for the C. trachomatis cpaf, tarp, and tox PCRs were designed with Primer Express software 
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version 3.0 (Applied Biosystems, Thermo Fisher Scientific), based on the complete genome sequences 
of C. trachomatis (NCBI Reference Sequence Database). The primers and probes were tested for 
specificity by the basic local alignment search tool (BLAST). The primers and probes were purchased 
from Applied Biosystems, Metabion and Oligomer. The primer and probe sequences and amplicon 
lengths are presented in Table 2. 
Table 2. Sequences of the cpaf, tarp, tox, and ompA primers and probes used in the real-time PCR 
analysis. 
Ctr 
Target 
Gene 
Amplicon 
Length 
Reference Primer/Probe (5´–3´) 
cpaf 86 bp This study 
Forward TAGGATGGGATCTTGTTCAAAGCT 
Reverse CTGCTGGCAAAAACTTGTTGAT 
Probe 6-FAM-CTGCACAGCAGAAGCTTCGTACACAAGAA-BHQ-1 
tarp 108 bp This study 
Forward CCTCTTCTGGAGATGATTCAGGAA 
Reverse TACGCACGGCAGAAAGGATA 
Probe 6-FAM-CCTCTGTCGGAAATGACGGACCTGCT-BHQ-1 
tox 106 bp This study 
Forward GATTCTTTAATTTCTGCTTGCTGAAA 
Reverse TGTTCGATCTCCTCAGTAGGAAGTTT 
Probe 6-FAM-CTCGGCAATATCAATGACGAAACGCGT-BHQ-1 
ompA 219 bp [22] 
Forward GACTTTGTTTTCGACCGTGTT 
Reverse ACARAATACATCAAARCGATCCCA 
Probe VIC-ATGTTTACVAAYGCYGCTT-MGB-NFQ 
Ctr—C. trachomatis. 
Real-time PCRs were performed in a 25 μL volume containing 12.5 μL Maxima Probe qPCR 
Master Mix (Thermo Fisher Scientific). The PCR for cpaf contained 600 nM primers and 200 nM 
probes, for tarp the PCR contained 300 nM primers and 200 nM probes, and for tox the PCR contained 
600 nM primers and 100 nM probes. The PCR analyses were performed on an ABI 7500 instrument 
and Sequence Detection Software version 1.3.1 (Applied Biosystems, Thermo Fisher Scientific). The 
thermal cycling conditions were two minutes at 50 C, ten minutes at 95 C, 40 cycles of 15 seconds 
at 95 C, and one minute at 60 C. The template volume was 2 μL of DNA and cDNA, and each 
sample was amplified in duplicate. 
To evaluate the performance of the C. trachomatis cpaf, tarp, and tox PCRs, DNA from C. 
trachomatis reference strains types A-L2 (ATCC numbers A:VR-571B, B:VR-573, C:VR-572, D:VR-885, 
E:VR-348B, F:VR-346, G:VR-878, H:VR-879, I:VR-880, J:VR-886, K:VR-887, and L2:VR-903) 
propagated in McCoy cells; C. pneumoniae isolate Kajaani-6 (from Pekka Saikku, University of Oulu, 
Finland) propagated in HL cells; eukaryotic cell lines A549, HL, and McCoy; and ten cervical swabs 
cultivated on agar plates (representing cervical bacterial flora) were tested. DNA was extracted from 
the bacteria on agar plates, as previously discussed [23]. The DNA was extracted from the other 
samples with either a MagNA Pure Compact instrument (Roche Diagnostics GmbH, Mannheim, 
Germany) using MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche Diagnostics GmbH), or 
with a DNeasy blood and tissue kit (Qiagen). 
To quantify the C. trachomatis GEs during HeLa229 cell infection, qPCR was applied to the 
extracted DNA and an external plasmid standard. A pIDTSMART-AMP plasmid containing the 
ompA PCR target sequence of C. trachomatis reference strain type E (Bour) was purchased from 
Integrated DNA Technologies (Coralville, IA, USA). Serially ten-fold diluted plasmid DNA (103–108 
copies/reaction) was amplified by the ompA PCR. The standard curve was generated by plotting the 
Ct values against the known initial plasmid copy numbers. The generation (doubling) time (i.e., the 
time interval required for the bacteria to divide) was calculated according to a formula from Todar´s 
Online Textbook of Bacteriology [24]. 
Real-time PCR was applied to study the ompA, cpaf, tarp, and tox expression. As an amplification 
control and a relative standard, serially ten-fold diluted C. trachomatis reference strain type E (Bour) 
DNA (10-1–10-6) was used. At each time after infection, the raw ompA, cpaf, tarp, and tox PCR 
amplification data was normalized against the number of C. trachomatis GEs in each sample [25]. To 
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detect chlamydial genomic DNA contamination and additional RT- control was amplified with every 
sample. No-template control was included in each run, to assess for reagent contamination.  
3. Results 
3.1. Clinical C. trachomatis Isolates 
Of the swabs from the 50 C. trachomatis NAAT positive females, we could culture 40 (80%) C. 
trachomatis isolates. Genotypes E (40%), F (20%), and G (13%) were the three most common. The 
genotype distribution was rather similar to the one described by us earlier [21]. The genotyping 
results have been confirmed by the whole genome sequencing of the isolates (the sequencing data 
have been deposited in the European Nucleotide Archive, ENA, http://www.ebi.ac.uk/ena) [26]. 
3.2. Growth Kinetics of C. trachomatis Reference Strains and Clinical Isolates 
At each time-point, the number of C. trachomatis GEs in the HeLa229 cultures was determined 
by ompA qPCR. The results are based on two technical replicates, and the experiment was repeated 
once with similar results. One-step growth curves showed that the exponential period of growth 
(exponential change in GEs) in the C. trachomatis reference strain type E and F took place at 12–36 hpi 
(Figure 1). In the clinical isolates, the exponential period of growth took place at 12–24 hpi in E127, at 
12–36 hpi in E142, F213 and F175, and at 24–36 hpi in E129. 
 
Figure 1. Growth kinetics of C. trachomatis reference strain type E (CtrE) and clinical isolates type E 
(E127, E129, and E142), and reference strain type F (CtrF) and clinical isolates type F (F213 and F175) 
at 2, 6, 12, 24, 36, and 48 hours post infection (hpi) in HeLa229 cells determined with ompA PCR. The 
stages of the chlamydial developmental cycle include early- (2–6 hpi), mid- (6–24 hpi), and late-stage 
(24–48 hpi). The results are shown as relative genome equivalents (GEs; the number of GEs at 2 hpi 
was set as one). The results are based on two experiments, both including two technical replicates. 
The generation time (time interval required for the division of bacteria) was calculated. A 
comparison of the number of GEs at the beginning and at the end of the exponential growth phase of 
C. trachomatis reference strain type E suggested a doubling time of 2.8 h, for the reference strain type 
F 2.9 h, and for the clinical isolate E127 2.2 h, whereas for the other clinical isolates, the doubling time 
was longer (E129 4.3 h, E142 4.0 h, F213 3.6 h, and F175 4.3 h). All of the clinical isolates, except one 
(E127), exhibited a slower growth rate than the reference strains.  
During the developmental cycle after the lag phase (6–12 hpi), the number of C. trachomatis GEs 
increased considerably when the reference strains were evaluated (2200-fold in C. trachomatis 
reference strain type E and 790-fold in reference strain type F). The overall fold-increase in the GEs 
of the clinical isolates was smaller, with an 11- to 190-fold increase in types E, and a 90- to 180-fold 
increase in types F. The reference strains propagated more efficiently progeny than the clinical isolates.  
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3.3. Performance of C. trachomatis cpaf, tarp, and tox Real-Time PCRs 
When C. trachomatis reference strain type E (Bour) DNA was amplified, the limit of detection for 
cpaf, tarp and tox PCRs corresponded to 1.6 inclusion forming units per reaction. Standard curve 
construction showed a linear relation between log values of DNA and PCR threshold cycles over five 
orders of magnitude. The efficiency of amplification was 99% (slope −3.358) for cpaf, 97% (slope 
−3.408) for tarp and 83% (slope −3.811) for tox PCR. To test for the specificity of the assays, DNA from 
C. trachomatis reference strains types A-L2, C. pneumoniae K6, cell lines A549, HL and McCoy, and 
ten cervical samples grown on agar plates were analyzed. The tarp and cpaf PCRs detected DNA from 
all C. trachomatis types while the rest of the samples tested negative. As expected, DNA from C. 
trachomatis types A, C and D-K tested positive by tox PCR, and the rest of the samples remained 
negative. In C. trachomatis type B, the entire cytotoxin gene region is deleted from the genome, and in 
types L1-3, there is an extensive deletion in the cytotoxin gene [27]. 
3.4. Expression of C. trachomatis ompA, cpaf, tarp, and tox Genes In Vitro 
The expression of the selected C. trachomatis genes was analyzed in infected HeLa229 cells at 2, 
6, 12, 24, 36, and 48 hpi. The results are based on two technical replicates and the experiment was 
repeated once, with similar results. C. trachomatis ompA was expressed between 12 and 48 hpi, and 
the peak of the expression was observed at 24 hpi in the reference strains and the clinical isolates 
(Figure 2). Among the reference strains and the clinical isolate E127, the ompA expression was high 
already at 12 hpi, compared with the other clinical isolates.  
 
 
Figure 2. The expression of the ompA, cpaf, tarp, and tox genes of C. trachomatis reference strain type E 
(CtrE), reference strain type F (CtrF), and five clinical isolates types of E and F (E127, E129, E142, F213, 
and F175) at 2, 6, 12, 24, 36, and 48 hours post infection in HeLa229 cells. The results are based on two 
technical replicates and the experiment was repeated once with similar results. At each time after 
infection, raw ompA, cpaf, tarp, and tox PCR amplification data were normalized against the number 
of C. trachomatis genome equivalents (GEs) in each sample [25]. 
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The expression of cpaf increased and peaked at 12 hpi in the clinical isolate E127, and at 24 hpi 
in the reference strains and the other clinical isolates. In addition, the cpaf expression was high at 6, 
12, and 24 hpi in the reference strain type E and at 24 hpi in the reference strain type F, compared 
with the clinical isolates. The expression of tarp was observed between 24 and 48 hpi. The reference 
strains and the clinical isolates had a rather similar tarp expression profile (Figure 2). The expression 
of tox was observed between 12 and 48 hpi, and the peak of the expression was at 12 hpi in the 
reference strains and the clinical isolate E127, and at 24 hpi in the other clinical isolates.  
The DNA and cDNA from the uninfected HeLa229 cell cultures were negative for all of the PCRs. 
The no-template control remained negative for all of the PCRs. Most of the RT- controls remained 
negative by PCR. However, some RT- controls from timepoints 36 and 48 hpi gave weak signals late 
in the PCR (Ct >37). 
3.5. Expression of C. trachomatis ompA, cpaf, tarp, and tox Genes in the Cervical Swabs 
Next, we attempted to analyze the transcriptional expression of the selected C. trachomatis genes 
directly in the cervical swab specimens. Small amounts of mRNA of one or several of the genes were 
detected in nine out of forty-four C. trachomatis NAAT positive samples—ompA mRNA in five, cpaf 
mRNA in five, tarp mRNA in three, and tox mRNA in three samples. In the eight C. trachomatis NAAT 
negative samples, no mRNA was detected. 
4. Discussion 
The long-term propagation of C. trachomatis in the cell culture can alter the regulation of the 
bacterial gene expression and lead to a faster growth rate [16–18]. For this study, low-passage-number 
C. trachomatis clinical isolates of two different genotypes were obtained from females attending an 
STI clinic. The growth characteristics and expression patterns of four genes among the five clinical 
isolates and two reference strains were analysed by PCR-based analyses. In agreement with earlier 
findings, the reference strains of type E and F exhibited a faster growth rate than four out of the five 
clinical low-passage-number isolates studied. Indeed, a doubling (generation) time of approximately 
two to three hours was estimated for the reference strains and one clinical isolate, whereas the other 
clinical isolates had a doubling time of approximately four hours. Likewise, a generation or doubling 
time of two to three hours has been estimated in urogenital C. trachomatis strains by others [25,28]. In 
addition, the reference strains propagated more efficiently than the clinical isolates in the cell culture 
conditions. These observed changes reflect the adaptation of multiple times passaged C. trachomatis 
reference strains to in vitro conditions [18,19]. This suggests that the use of low-passage-number 
isolates in experimental approaches might better mimic the situation during infection. However, to 
our surprise, one of the low-passage-number isolates, E127, exhibited characteristics similar to the 
reference strains. The isolate was cultured from a cervical swab of an asymptomatic, seronegative 
female, whose partner had tested C. trachomatis positive (Table 1). The clinical data available suggests 
that she could be experiencing her first C. trachomatis infection, but the ultimate factors explaining 
the growth properties of the bacteria remain undefined. The other isolates studied were from C. 
trachomatis seropositive females suffering from or possibly having repeated C. trachomatis infection. 
For the first time, the in vitro expression of the C. trachomatis cpaf, tarp, and tox genes was studied 
at different stages of the chlamydial developmental cycle using low-passage-number clinical isolates 
of types E and F. We observed dissimilarities in the C. trachomatis gene expression profile between 
the low-passage-number clinical isolates and the reference strains. The expression of cpaf was high at 
the mid-phase of the developmental cycle in the reference strains, compared with the clinical isolates. 
The relevance of this remains unknown, as the precise target molecules of CPAF and the role of this 
protease during chlamydial infection are under reevaluation [12]. The peak of expression for tox (at 
12 hpi) was also observed earlier in the reference strains than for most clinical isolates (24 hpi). The 
toxin has a role early during developmental cycle [13], so this might also associate with the faster 
growth of these strains. Only the expression profile of tarp was rather similar among the clinical 
isolates and the reference strains. The expression of tarp was observed later than that of the other 
Microorganisms 2019, 7, 153 8 of 10 
 
genes. Indeed, in earlier studies, the type L2 tarp expression was categorized as late (24–36 hpi) [6] or 
type D tarp expressed at 8–40 hpi [7].  
The expression of ompA (starting at 12 hpi) took place earlier in the reference strains and one 
clinical isolate than in the other clinical isolates. This might reflect the role of MOMP as a major 
structural component of the cell membrane in dividing RBs. The observed variation in the 
transcriptional expression among the clinical isolates is probably due to the intrinsic properties of the 
single isolates because the growth conditions were identical. Infected HeLa229 cell cultures were 
used in these experiments, as they represent the most established C. trachomatis infection models and 
have extensively been used previously [19,29]. Moreover, the ompA expression data obtained with 
the reference strains in this model were in line with the earlier data [7,19,30], suggesting that the 
infection model used by us is comparable to those used in the previous studies. In some previous 
studies, the data were achieved with microarray or RNA sequencing techniques. However, it has 
been demonstrated that the RT-PCR data correlates well with the data obtained by both techniques 
[6,7,31]. 
The mRNA of the C. trachomatis ompA, tox, tarp, and cpaf genes was infrequently detected in the 
cervical swabs, although the corresponding low-passage-number isolates readily expressed these 
genes in vitro. This suggests that the absence of a signal in the cervical swabs can be due to the small 
amount of chlamydial mRNA in the samples, and not to a variation in gene expression during in vivo 
infection. This is further supported by serology, in which the responses to the proteins encoded by 
genes ompA, cpaf, tarp, and tox were observed in the sera from C. trachomatis seropositive patients (our 
unpublished observation). The few studies on the in vivo gene expression of C. trachomatis analyzed 
that the cytobrush cervical samples [32] or synovial biopsies [33] probably contain more C. trachomatis 
cells than cervical swabs. Moreover, as C. trachomatis could be cultured, the swab specimens 
contained chlamydial EBs, but the presence of RBs (metabolically active forms) remains unknown. 
The strengths of our approach include the use of characterized, low-passage-number C. 
trachomatis clinical isolates, and an established cell culture model of infection. Also, we used the 
relative quantitation of cDNA, which allows for the comparison of the gene expression between 
different timepoints. We chose to use chlamydial genomic DNA in the normalization of the gene 
expression data. Although the number of genomes per bacteria might vary slightly during 
replication, this approach has proven appropriate [25,34,35]. One weakness is that the determination 
of the mRNA and genomic DNA are experimentally independent, which could create a bias in the 
gene expression patterns. Also, the mRNA decay rate was not analyzed. 
Studies on the C. trachomatis gene expression and growth kinetics during in vitro and in vivo 
infection promote an understanding of the disease pathogenesis, as well as finding novel therapeutic 
options. Transcriptomics remain an essential tool in such studies. In the future, the challenges in the 
in vivo gene expression studies of C. trachomatis may be overcome with the development of more 
sensitive transcriptome analysis methods such as single-cell RNA sequencing [36]. Here, the C. 
trachomatis low-passage-number clinical isolates acted differently compared to the reference strains. 
This calls for the careful evaluation of the strains used in chlamydial research. In general, the use of 
characterized C. trachomatis low-passage-number isolates is encouraged, as it could better reflect the 
situation in vivo during culture-positive infection than the use of the readily available reference 
strains.  
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